Comparison of 5 Different Remifentanil Strategies Against Myocardial Ischemia-Reperfusion Injury
Objective The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury. Design An in vitro experimental study using the Langendorff system. Setting A university r...
Saved in:
Published in | Journal of cardiothoracic and vascular anesthesia Vol. 25; no. 6; pp. 926 - 930 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.12.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury. Design An in vitro experimental study using the Langendorff system. Setting A university research laboratory. Participants Male Sprague-Dawley rats (each n = 9). Interventions Five different remifentanil strategies were performed in isolated rat hearts as follows: remifentanil preconditioning (R-Pre), remifentanil postconditioning (R-Post), ischemic targeting remifentanil (R1), reperfusion targeting remifentanil (R2), or both ischemic and reperfusion targeting remifentanil (R3). Infarct size and cardiodynamics were compared. Measurement and Main Results The infarct-risk volume ratio in groups R-Pre (13.7% ± 9.9%), R-Post (13.7% ± 12.3%), and R3 (12.6% ± 6.1%) were decreased significantly compared with the untreated control hearts (32.9% ± 11.1%, p < 0.01). There was no significant difference in the left ventricular–developed pressure (LVDP) recovery after reperfusion between the control (43.6% ± 14.5%) and R-Pre (34.8% ± 12.9%, p > 0.05) groups after reperfusion. However, the LVDP recovery in R-Post (21.6% ± 7.7%, p < 0.05), R1 (16.7% ± 19.8%, p < 0.01), R2 (22.2% ± 13.9%, p < 0.05), and R3 (16.2% ± 7.8%, p < 0.01) was decreased significantly compared with control hearts. There was no significant difference in the recovery of dP/dtmax after reperfusion between the R-Pre (42.0% ± 16.9%) and control groups (39.0% ± 15.4%, p > 0.05), whereas the dP/dtmax in R3 group (16.9% ± 9.0%) was decreased significantly compared with R-Pre ( p < 0.05). Conclusions Preconditioning or postconditioning by remifentanil and the continuous infusion of remifentanil effectively reduce myocardial infarction, whereas reperfusion targeting ischemic targeting or reperfusion targeting remifentanil does not. Remifentanil preconditioning better preserves myocardial function, especially LVDP, than other remifentanil strategies. |
---|---|
AbstractList | The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury.
An in vitro experimental study using the Langendorff system.
A university research laboratory.
Male Sprague-Dawley rats (each n = 9).
Five different remifentanil strategies were performed in isolated rat hearts as follows: remifentanil preconditioning (R-Pre), remifentanil postconditioning (R-Post), ischemic targeting remifentanil (R1), reperfusion targeting remifentanil (R2), or both ischemic and reperfusion targeting remifentanil (R3). Infarct size and cardiodynamics were compared.
The infarct-risk volume ratio in groups R-Pre (13.7% ± 9.9%), R-Post (13.7% ± 12.3%), and R3 (12.6% ± 6.1%) were decreased significantly compared with the untreated control hearts (32.9% ± 11.1%,
p < 0.01). There was no significant difference in the left ventricular–developed pressure (LVDP) recovery after reperfusion between the control (43.6% ± 14.5%) and R-Pre (34.8% ± 12.9%,
p > 0.05) groups after reperfusion. However, the LVDP recovery in R-Post (21.6% ± 7.7%,
p < 0.05), R1 (16.7% ± 19.8%,
p < 0.01), R2 (22.2% ± 13.9%,
p < 0.05), and R3 (16.2% ± 7.8%,
p < 0.01) was decreased significantly compared with control hearts. There was no significant difference in the recovery of dP/dt
max after reperfusion between the R-Pre (42.0% ± 16.9%) and control groups (39.0% ± 15.4%,
p > 0.05), whereas the dP/dt
max in R3 group (16.9% ± 9.0%) was decreased significantly compared with R-Pre (
p < 0.05).
Preconditioning or postconditioning by remifentanil and the continuous infusion of remifentanil effectively reduce myocardial infarction, whereas reperfusion targeting ischemic targeting or reperfusion targeting remifentanil does not. Remifentanil preconditioning better preserves myocardial function, especially LVDP, than other remifentanil strategies. Objective The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury. Design An in vitro experimental study using the Langendorff system. Setting A university research laboratory. Participants Male Sprague-Dawley rats (each n = 9). Interventions Five different remifentanil strategies were performed in isolated rat hearts as follows: remifentanil preconditioning (R-Pre), remifentanil postconditioning (R-Post), ischemic targeting remifentanil (R1), reperfusion targeting remifentanil (R2), or both ischemic and reperfusion targeting remifentanil (R3). Infarct size and cardiodynamics were compared. Measurement and Main Results The infarct-risk volume ratio in groups R-Pre (13.7% ± 9.9%), R-Post (13.7% ± 12.3%), and R3 (12.6% ± 6.1%) were decreased significantly compared with the untreated control hearts (32.9% ± 11.1%, p < 0.01). There was no significant difference in the left ventricular–developed pressure (LVDP) recovery after reperfusion between the control (43.6% ± 14.5%) and R-Pre (34.8% ± 12.9%, p > 0.05) groups after reperfusion. However, the LVDP recovery in R-Post (21.6% ± 7.7%, p < 0.05), R1 (16.7% ± 19.8%, p < 0.01), R2 (22.2% ± 13.9%, p < 0.05), and R3 (16.2% ± 7.8%, p < 0.01) was decreased significantly compared with control hearts. There was no significant difference in the recovery of dP/dtmax after reperfusion between the R-Pre (42.0% ± 16.9%) and control groups (39.0% ± 15.4%, p > 0.05), whereas the dP/dtmax in R3 group (16.9% ± 9.0%) was decreased significantly compared with R-Pre ( p < 0.05). Conclusions Preconditioning or postconditioning by remifentanil and the continuous infusion of remifentanil effectively reduce myocardial infarction, whereas reperfusion targeting ischemic targeting or reperfusion targeting remifentanil does not. Remifentanil preconditioning better preserves myocardial function, especially LVDP, than other remifentanil strategies. OBJECTIVEThe purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury.DESIGNAn in vitro experimental study using the Langendorff system.SETTINGA university research laboratory.PARTICIPANTSMale Sprague-Dawley rats (each n = 9).INTERVENTIONSFive different remifentanil strategies were performed in isolated rat hearts as follows: remifentanil preconditioning (R-Pre), remifentanil postconditioning (R-Post), ischemic targeting remifentanil (R1), reperfusion targeting remifentanil (R2), or both ischemic and reperfusion targeting remifentanil (R3). Infarct size and cardiodynamics were compared.MEASUREMENT AND MAIN RESULTSThe infarct-risk volume ratio in groups R-Pre (13.7% ± 9.9%), R-Post (13.7% ± 12.3%), and R3 (12.6% ± 6.1%) were decreased significantly compared with the untreated control hearts (32.9% ± 11.1%, p < 0.01). There was no significant difference in the left ventricular-developed pressure (LVDP) recovery after reperfusion between the control (43.6% ± 14.5%) and R-Pre (34.8% ± 12.9%, p > 0.05) groups after reperfusion. However, the LVDP recovery in R-Post (21.6% ± 7.7%, p < 0.05), R1 (16.7% ± 19.8%, p < 0.01), R2 (22.2% ± 13.9%, p < 0.05), and R3 (16.2% ± 7.8%, p < 0.01) was decreased significantly compared with control hearts. There was no significant difference in the recovery of dP/dt(max) after reperfusion between the R-Pre (42.0% ± 16.9%) and control groups (39.0% ± 15.4%, p > 0.05), whereas the dP/dt(max) in R3 group (16.9% ± 9.0%) was decreased significantly compared with R-Pre (p < 0.05).CONCLUSIONSPreconditioning or postconditioning by remifentanil and the continuous infusion of remifentanil effectively reduce myocardial infarction, whereas reperfusion targeting ischemic targeting or reperfusion targeting remifentanil does not. Remifentanil preconditioning better preserves myocardial function, especially LVDP, than other remifentanil strategies. The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against myocardial ischemia-reperfusion injury. An in vitro experimental study using the Langendorff system. A university research laboratory. Male Sprague-Dawley rats (each n = 9). Five different remifentanil strategies were performed in isolated rat hearts as follows: remifentanil preconditioning (R-Pre), remifentanil postconditioning (R-Post), ischemic targeting remifentanil (R1), reperfusion targeting remifentanil (R2), or both ischemic and reperfusion targeting remifentanil (R3). Infarct size and cardiodynamics were compared. The infarct-risk volume ratio in groups R-Pre (13.7% ± 9.9%), R-Post (13.7% ± 12.3%), and R3 (12.6% ± 6.1%) were decreased significantly compared with the untreated control hearts (32.9% ± 11.1%, p < 0.01). There was no significant difference in the left ventricular-developed pressure (LVDP) recovery after reperfusion between the control (43.6% ± 14.5%) and R-Pre (34.8% ± 12.9%, p > 0.05) groups after reperfusion. However, the LVDP recovery in R-Post (21.6% ± 7.7%, p < 0.05), R1 (16.7% ± 19.8%, p < 0.01), R2 (22.2% ± 13.9%, p < 0.05), and R3 (16.2% ± 7.8%, p < 0.01) was decreased significantly compared with control hearts. There was no significant difference in the recovery of dP/dt(max) after reperfusion between the R-Pre (42.0% ± 16.9%) and control groups (39.0% ± 15.4%, p > 0.05), whereas the dP/dt(max) in R3 group (16.9% ± 9.0%) was decreased significantly compared with R-Pre (p < 0.05). Preconditioning or postconditioning by remifentanil and the continuous infusion of remifentanil effectively reduce myocardial infarction, whereas reperfusion targeting ischemic targeting or reperfusion targeting remifentanil does not. Remifentanil preconditioning better preserves myocardial function, especially LVDP, than other remifentanil strategies. |
Author | Park, Yong Hyun, MD, PhD Kim, Jun, MD, PhD Kim, June Hong, MD, PhD Lee, Mi Young, MD, PhD Chun, Kook Jin, MD, PhD Kim, Jeong Su, MD Jang, Youngho, MD, PhD |
Author_xml | – sequence: 1 fullname: Chun, Kook Jin, MD, PhD – sequence: 2 fullname: Park, Yong Hyun, MD, PhD – sequence: 3 fullname: Kim, Jeong Su, MD – sequence: 4 fullname: Jang, Youngho, MD, PhD – sequence: 5 fullname: Kim, June Hong, MD, PhD – sequence: 6 fullname: Kim, Jun, MD, PhD – sequence: 7 fullname: Lee, Mi Young, MD, PhD |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21514843$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtv1DAUhS1URB_wB1ig7FglXMdxHhJCqgZaRmpVqe2CnblxbopDYg92Umn-PY6mdNEFKx9L3zmSP5-yI-ssMfaeQ8ZBik9DNjxqzHLgPIM8A968Yidcijytizw_ijlSKVQVHLPTEAaIoJTVG3acc8mLuhAn7OfGTTv0JjibuD6RyVfT9-TJzsktTaaPAa0Zk7vZ40wPhkJy_oDGhjm53juNvjM4Jtugf0Ua01vake-XYOLc1g6L379lr3scA717Os_Y_cW3-8339Ormcrs5v0p1wWFOS8EBoeGilDlViD1KKluuy7IVvIA6XmtoW5QVyrYsRCckNFjVHei-LVpxxj4eZnfe_VkozGoyQdM4oiW3BNVAKWXDa4hkfiC1dyF46tXOmwn9XnFQqzE1qNWrWr0qyFX0GksfnuaXdqLuufJPZAQ-HwCKb3w05FXQhqymznjSs-qc-f_-lxd1PRprNI6_aU9hcIu30Z7iKsSCult31o_lHCDGH-IvvLGghA |
CitedBy_id | crossref_primary_10_1016_j_jss_2015_01_010 crossref_primary_10_1155_2019_9836302 crossref_primary_10_5812_aapm_42505 crossref_primary_10_1016_j_biopha_2023_115472 crossref_primary_10_1155_2014_846570 crossref_primary_10_1186_1471_230X_13_69 crossref_primary_10_1590_S0102_865020150110000006 crossref_primary_10_3389_fphar_2018_01083 crossref_primary_10_1016_j_biopha_2022_113751 crossref_primary_10_1016_j_jss_2013_02_058 crossref_primary_10_1002_med_21395 crossref_primary_10_1016_j_surg_2015_07_028 crossref_primary_10_1053_j_jvca_2015_01_021 crossref_primary_10_1097_CCM_0000000000001350 crossref_primary_10_4097_kjae_2012_63_4_340 crossref_primary_10_18632_aging_103604 crossref_primary_10_1016_j_bjane_2013_09_007 crossref_primary_10_1016_j_ejphar_2018_03_030 crossref_primary_10_1155_2019_3013716 crossref_primary_10_1016_j_bjan_2013_09_006 crossref_primary_10_3389_fphar_2018_00729 crossref_primary_10_1016_j_ejphar_2022_175094 |
Cites_doi | 10.1097/01.anes.0000299437.93898.4a 10.1097/00019501-200411000-00013 10.1152/ajpheart.00233.2006 10.1006/jmcc.1997.0454 10.1097/00000542-200410000-00017 10.1152/ajpheart.01064.2002 10.1007/s10557-006-6257-7 10.1007/s11373-005-7401-2 10.1093/bja/86.6.846 10.1097/00005344-200403000-00012 10.1111/j.1399-6576.2009.02145.x 10.1016/j.vph.2005.02.003 10.1016/j.jss.2007.07.020 10.33549/physiolres.931772 10.1097/00000542-200502000-00020 10.1111/j.1745-7254.2005.00100.x 10.1016/j.athoracsur.2004.03.033 10.1124/jpet.106.101477 10.1152/ajpheart.01143.2003 |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2011 Elsevier Inc. Copyright © 2011 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: Elsevier Inc. – notice: 2011 Elsevier Inc. – notice: Copyright © 2011 Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1053/j.jvca.2011.02.019 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-8422 |
EndPage | 930 |
ExternalDocumentID | 10_1053_j_jvca_2011_02_019 21514843 S105307701100053X 1_s2_0_S105307701100053X |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXKI AAXUO ABBQC ABFRF ABJNI ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM M29 M41 MO0 N9A O-L O9- O90 OAUVE OL- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSZ T5K UHS UNMZH UV1 WUQ Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c410t-6310a0913652e7aafa5e6b1c66b31408a5e80bba57a5b643d3509a78d0cfb4b3 |
IEDL.DBID | AIKHN |
ISSN | 1053-0770 |
IngestDate | Fri Aug 16 00:17:33 EDT 2024 Thu Sep 26 18:07:28 EDT 2024 Sat Sep 28 08:00:12 EDT 2024 Fri Feb 23 02:34:48 EST 2024 Tue Oct 15 22:54:13 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | postconditioning myocardial ischemia remifentanil cardiodynamics preconditioning |
Language | English |
License | Copyright © 2011 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c410t-6310a0913652e7aafa5e6b1c66b31408a5e80bba57a5b643d3509a78d0cfb4b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21514843 |
PQID | 906559180 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_906559180 crossref_primary_10_1053_j_jvca_2011_02_019 pubmed_primary_21514843 elsevier_sciencedirect_doi_10_1053_j_jvca_2011_02_019 elsevier_clinicalkeyesjournals_1_s2_0_S105307701100053X |
PublicationCentury | 2000 |
PublicationDate | 2011-12-01 |
PublicationDateYYYYMMDD | 2011-12-01 |
PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of cardiothoracic and vascular anesthesia |
PublicationTitleAlternate | J Cardiothorac Vasc Anesth |
PublicationYear | 2011 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Wong, Li, Jiang (bib5) 2010; 54 Park, Zhao, Jang (bib6) 2006; 318 Schultz, Hsu, Gross (bib1) 1997; 29 Zhang, Irwin, Wong (bib4) 2004; 101 Chang, Lee, Su (bib9) 2005; 12 Chen, Li, Zhang (bib12) 2008; 145 Peart, Gross, Gross (bib11) 2005; 42 Halkos, Kerendi, Corvera (bib16) 2004; 78 Peart, Gross, Gross (bib3) 2004; 43 Zhang, Irwin, Wong (bib7) 2005; 102 Peart, Gross (bib10) 2006; 291 Kuzume, Wolff, Chien (bib18) 2004; 15 Kim, Cho, Hong (bib14) 2010; 59 Moolman, Hartley, Van Wyk (bib15) 2006; 20 Zhao, Corvera, Halkos (bib17) 2003; 285 Jang, Xi, Wang (bib8) 2008; 108 Ebel, Lipfert, Frabdorf (bib19) 2001; 86 Okubo, Tanabe, Takeda (bib2) 2004; 287 Zhang, Chen, Girwin (bib13) 2005; 26 Schultz (10.1053/j.jvca.2011.02.019_bib1) 1997; 29 Park (10.1053/j.jvca.2011.02.019_bib6) 2006; 318 Zhang (10.1053/j.jvca.2011.02.019_bib7) 2005; 102 Okubo (10.1053/j.jvca.2011.02.019_bib2) 2004; 287 Zhao (10.1053/j.jvca.2011.02.019_bib17) 2003; 285 Peart (10.1053/j.jvca.2011.02.019_bib11) 2005; 42 Kim (10.1053/j.jvca.2011.02.019_bib14) 2010; 59 Moolman (10.1053/j.jvca.2011.02.019_bib15) 2006; 20 Zhang (10.1053/j.jvca.2011.02.019_bib4) 2004; 101 Wong (10.1053/j.jvca.2011.02.019_bib5) 2010; 54 Ebel (10.1053/j.jvca.2011.02.019_bib19) 2001; 86 Jang (10.1053/j.jvca.2011.02.019_bib8) 2008; 108 Chen (10.1053/j.jvca.2011.02.019_bib12) 2008; 145 Chang (10.1053/j.jvca.2011.02.019_bib9) 2005; 12 Kuzume (10.1053/j.jvca.2011.02.019_bib18) 2004; 15 Halkos (10.1053/j.jvca.2011.02.019_bib16) 2004; 78 Peart (10.1053/j.jvca.2011.02.019_bib3) 2004; 43 Peart (10.1053/j.jvca.2011.02.019_bib10) 2006; 291 Zhang (10.1053/j.jvca.2011.02.019_bib13) 2005; 26 |
References_xml | – volume: 108 start-page: 243 year: 2008 end-page: 250 ident: bib8 article-title: Postconditioning prevents reperfusion injury by activating delta-opioid receptors publication-title: Anesthesiology contributor: fullname: Wang – volume: 29 start-page: 2187 year: 1997 end-page: 2195 ident: bib1 article-title: Ischemic preconditioning and morphine-induced cardioprotection involve the delta-opioid receptor in the intact rat heart publication-title: J Mol Cell Cardiol contributor: fullname: Gross – volume: 54 start-page: 510 year: 2010 end-page: 518 ident: bib5 article-title: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta receptor activation publication-title: Acta Anaesthesiol Scand contributor: fullname: Jiang – volume: 101 start-page: 918 year: 2004 end-page: 923 ident: bib4 article-title: Remifentanil preconditioning protects against ischemic injury in the intact rat heart publication-title: Anesthesiology contributor: fullname: Wong – volume: 145 start-page: 287 year: 2008 end-page: 294 ident: bib12 article-title: Morphine postconditioning protects against reperfusion injury in the isolated rat hearts publication-title: J Surg Res contributor: fullname: Zhang – volume: 59 start-page: 347 year: 2010 end-page: 356 ident: bib14 article-title: Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart publication-title: Physiol Res contributor: fullname: Hong – volume: 285 start-page: H579 year: 2003 end-page: H588 ident: bib17 article-title: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning publication-title: Am J Physiol Heart Circ Physiol contributor: fullname: Halkos – volume: 102 start-page: 371 year: 2005 end-page: 378 ident: bib7 article-title: Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors publication-title: Anesthesioloy contributor: fullname: Wong – volume: 318 start-page: 124 year: 2006 end-page: 131 ident: bib6 article-title: N publication-title: J Pharmacol Exp Ther contributor: fullname: Jang – volume: 291 start-page: H1746 year: 2006 end-page: H1753 ident: bib10 article-title: Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways publication-title: Am J Physiol Heart Circ Physiol contributor: fullname: Gross – volume: 43 start-page: 410 year: 2004 end-page: 415 ident: bib3 article-title: Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction publication-title: J Cardiovasc Pharmacol contributor: fullname: Gross – volume: 78 start-page: 961 year: 2004 end-page: 969 ident: bib16 article-title: Myocardial protection with postconditioning is not enhanced by ischemic preconditioning publication-title: Ann Thorac Surg contributor: fullname: Corvera – volume: 42 start-page: 211 year: 2005 end-page: 218 ident: bib11 article-title: Opioid-induced preconditioning: Recent advances and future perspectives publication-title: Vascul Pharmacol contributor: fullname: Gross – volume: 20 start-page: 13 year: 2006 end-page: 25 ident: bib15 article-title: Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK publication-title: Cardiovasc Drugs Ther contributor: fullname: Van Wyk – volume: 12 start-page: 611 year: 2005 end-page: 619 ident: bib9 article-title: Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts publication-title: J Biomed Sci contributor: fullname: Su – volume: 15 start-page: 449 year: 2004 end-page: 455 ident: bib18 article-title: Remifentanil limits infarct size but attenuates preconditioning-induced infarct limitation publication-title: Coron Artery Dis contributor: fullname: Chien – volume: 86 start-page: 846 year: 2001 end-page: 852 ident: bib19 article-title: Lidocaine reduces ischaemic but not reperfusion injury in isolated rat heart publication-title: Br J Anaesth contributor: fullname: Frabdorf – volume: 287 start-page: H1786 year: 2004 end-page: H1791 ident: bib2 article-title: Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: Role of delta-opioid receptor publication-title: Am J Physiol Heart Circ Physiol contributor: fullname: Takeda – volume: 26 start-page: 546 year: 2005 end-page: 550 ident: bib13 article-title: Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats publication-title: Acta Pharmacol Sin contributor: fullname: Girwin – volume: 108 start-page: 243 year: 2008 ident: 10.1053/j.jvca.2011.02.019_bib8 article-title: Postconditioning prevents reperfusion injury by activating delta-opioid receptors publication-title: Anesthesiology doi: 10.1097/01.anes.0000299437.93898.4a contributor: fullname: Jang – volume: 15 start-page: 449 year: 2004 ident: 10.1053/j.jvca.2011.02.019_bib18 article-title: Remifentanil limits infarct size but attenuates preconditioning-induced infarct limitation publication-title: Coron Artery Dis doi: 10.1097/00019501-200411000-00013 contributor: fullname: Kuzume – volume: 291 start-page: H1746 year: 2006 ident: 10.1053/j.jvca.2011.02.019_bib10 article-title: Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.00233.2006 contributor: fullname: Peart – volume: 29 start-page: 2187 year: 1997 ident: 10.1053/j.jvca.2011.02.019_bib1 article-title: Ischemic preconditioning and morphine-induced cardioprotection involve the delta-opioid receptor in the intact rat heart publication-title: J Mol Cell Cardiol doi: 10.1006/jmcc.1997.0454 contributor: fullname: Schultz – volume: 101 start-page: 918 year: 2004 ident: 10.1053/j.jvca.2011.02.019_bib4 article-title: Remifentanil preconditioning protects against ischemic injury in the intact rat heart publication-title: Anesthesiology doi: 10.1097/00000542-200410000-00017 contributor: fullname: Zhang – volume: 285 start-page: H579 year: 2003 ident: 10.1053/j.jvca.2011.02.019_bib17 article-title: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.01064.2002 contributor: fullname: Zhao – volume: 20 start-page: 13 year: 2006 ident: 10.1053/j.jvca.2011.02.019_bib15 article-title: Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK publication-title: Cardiovasc Drugs Ther doi: 10.1007/s10557-006-6257-7 contributor: fullname: Moolman – volume: 12 start-page: 611 year: 2005 ident: 10.1053/j.jvca.2011.02.019_bib9 article-title: Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts publication-title: J Biomed Sci doi: 10.1007/s11373-005-7401-2 contributor: fullname: Chang – volume: 86 start-page: 846 year: 2001 ident: 10.1053/j.jvca.2011.02.019_bib19 article-title: Lidocaine reduces ischaemic but not reperfusion injury in isolated rat heart publication-title: Br J Anaesth doi: 10.1093/bja/86.6.846 contributor: fullname: Ebel – volume: 43 start-page: 410 year: 2004 ident: 10.1053/j.jvca.2011.02.019_bib3 article-title: Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction publication-title: J Cardiovasc Pharmacol doi: 10.1097/00005344-200403000-00012 contributor: fullname: Peart – volume: 54 start-page: 510 year: 2010 ident: 10.1053/j.jvca.2011.02.019_bib5 article-title: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta receptor activation publication-title: Acta Anaesthesiol Scand doi: 10.1111/j.1399-6576.2009.02145.x contributor: fullname: Wong – volume: 42 start-page: 211 year: 2005 ident: 10.1053/j.jvca.2011.02.019_bib11 article-title: Opioid-induced preconditioning: Recent advances and future perspectives publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2005.02.003 contributor: fullname: Peart – volume: 145 start-page: 287 year: 2008 ident: 10.1053/j.jvca.2011.02.019_bib12 article-title: Morphine postconditioning protects against reperfusion injury in the isolated rat hearts publication-title: J Surg Res doi: 10.1016/j.jss.2007.07.020 contributor: fullname: Chen – volume: 59 start-page: 347 year: 2010 ident: 10.1053/j.jvca.2011.02.019_bib14 article-title: Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart publication-title: Physiol Res doi: 10.33549/physiolres.931772 contributor: fullname: Kim – volume: 102 start-page: 371 year: 2005 ident: 10.1053/j.jvca.2011.02.019_bib7 article-title: Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors publication-title: Anesthesioloy doi: 10.1097/00000542-200502000-00020 contributor: fullname: Zhang – volume: 26 start-page: 546 year: 2005 ident: 10.1053/j.jvca.2011.02.019_bib13 article-title: Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats publication-title: Acta Pharmacol Sin doi: 10.1111/j.1745-7254.2005.00100.x contributor: fullname: Zhang – volume: 78 start-page: 961 year: 2004 ident: 10.1053/j.jvca.2011.02.019_bib16 article-title: Myocardial protection with postconditioning is not enhanced by ischemic preconditioning publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2004.03.033 contributor: fullname: Halkos – volume: 318 start-page: 124 year: 2006 ident: 10.1053/j.jvca.2011.02.019_bib6 article-title: N6-(3-Iodobenzyl)-adenosine-5'-N-methylcarboamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.106.101477 contributor: fullname: Park – volume: 287 start-page: H1786 year: 2004 ident: 10.1053/j.jvca.2011.02.019_bib2 article-title: Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: Role of delta-opioid receptor publication-title: Am J Physiol Heart Circ Physiol doi: 10.1152/ajpheart.01143.2003 contributor: fullname: Okubo |
SSID | ssj0011557 |
Score | 2.1610975 |
Snippet | Objective The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous... The purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous infusion) against... OBJECTIVEThe purpose of this study was to investigate the effects of various remifentanil strategies (preconditioning, postconditioning, or continuous... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 926 |
SubjectTerms | Anesthesia & Perioperative Care Anesthetics, Intravenous - administration & dosage Anesthetics, Intravenous - pharmacology Animals Body Weight - physiology cardiodynamics Cardiotonic Agents Coloring Agents Coronary Circulation - physiology Critical Care Heart - drug effects Heart Function Tests In Vitro Techniques Ischemic Postconditioning - methods Ischemic Preconditioning, Myocardial - methods Male Myocardial Infarction - pathology Myocardial Infarction - prevention & control myocardial ischemia Myocardial Reperfusion Injury - prevention & control Organ Size - physiology Piperidines - administration & dosage Piperidines - pharmacology postconditioning preconditioning Rats Rats, Sprague-Dawley remifentanil Reperfusion Tetrazolium Salts Ventricular Function, Left - physiology |
Title | Comparison of 5 Different Remifentanil Strategies Against Myocardial Ischemia-Reperfusion Injury |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S105307701100053X https://dx.doi.org/10.1053/j.jvca.2011.02.019 https://www.ncbi.nlm.nih.gov/pubmed/21514843 https://search.proquest.com/docview/906559180 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCbaFBh2Gbrulb6gQ2-DEz8kP45B2iLZkB62DshNo2xpcNA6RZ0U6KW_vZQiBxi67bCbZUiQTVLkR5GiAM5MXJiEzGQQZ4ocFDRJkJNrG0RcFEWVqCh2lZhmV-nkB_8yF_MdGHdnYWxapdf9G53utLV_M_TUHN7V9fA7IQMS0MwVPaPH-S7skTnivAd7o-nXydU2mEAm092xQp0CO8CfnaHmcDFYPJToK3nGA1dw58_26W_409mhy3144wEkG22-8S3s6OYAXs18iPwd_BxvbxZkS8MEO_dXoKzYN31bG5sr3tQ3rCtLq1s2-oU1oUQ2eyTDZgXmhk3J6aXeGBBA1_dmbffU2LRZEAfew_XlxfV4EvhrFIKSR-EqSAnBoS3_mYpYZ4gGhU5VVKapSsi9yqmZh0qhyFAoAihVQiACs7wKS6O4Sj5Ar1k2-hMwQlc6NBWiwoKXaYVFxcMK6amwGTS8D5872sm7TbEM6YLcIiEnw1JaWkrLMJZE6T5kHXlldwyUFJdu_SpqZSRb6ilfcLoPYjvyN2GRZAf-OSPruChpFdnQCDZ6uW5lQUhMFFEe9uHjhrvbH7CYiOc8OfzPSY_gtduHdikwx9Bb3a_1CQGZlTqF3cFTdOrF9RlhrfDI |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa6FNh6KfZuukd12G1w44fkxzHIViRtk8OWAblplC0VDjqnqJMC_fejFDnAsK2H3ixDgmySIj-KFAXwycSFSchMBnGmyEFBkwQ5ubZBxEVRVImKYleJaTpLxz_4-UIs9mDUnYWxaZVe9291utPW_s3AU3NwU9eD74QMSEAzV_SMHhdPYJ-LLIp7sD-cXIxnu2ACmUx3xwp1CuwAf3aGmoPl6fKuRF_JMz51BXf-bZ_-hz-dHTp7DoceQLLh9htfwJ5uXsLTqQ-Rv4Kfo93NgmxlmGBf_BUoa_ZN_6qNzRVv6mvWlaXVLRteYU0okU3vybBZgblmE3J6qTcGBND1rdnYPTU2aZbEgdcwP_s6H40Df41CUPIoXAcpITi05T9TEesM0aDQqYrKNFUJuVc5NfNQKRQZCkUApUoIRGCWV2FpFFfJG-g1q0YfASN0pUNTISoseJlWWFQ8rJCeCptBw_vwuaOdvNkWy5AuyC0ScjIspaWltAxjSZTuQ9aRV3bHQElx6davolZGsqWe8i9O90HsRv4hLJLswIMzso6LklaRDY1go1ebVhaExEQR5WEf3m65u_sBi4l4zpPjR056As_G8-mlvJzMLt7BgduTdukw76G3vt3oDwRq1uqjF9rfKvbyuA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+5+Different+Remifentanil+Strategies+Against+Myocardial+Ischemia-Reperfusion+Injury&rft.jtitle=Journal+of+cardiothoracic+and+vascular+anesthesia&rft.au=Chun%2C+Kook+Jin%2C+MD%2C+PhD&rft.au=Park%2C+Yong+Hyun%2C+MD%2C+PhD&rft.au=Kim%2C+Jeong+Su%2C+MD&rft.au=Jang%2C+Youngho%2C+MD%2C+PhD&rft.date=2011-12-01&rft.issn=1053-0770&rft.volume=25&rft.issue=6&rft.spage=926&rft.epage=930&rft_id=info:doi/10.1053%2Fj.jvca.2011.02.019&rft.externalDBID=ECK1-s2.0-S105307701100053X&rft.externalDocID=1_s2_0_S105307701100053X |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10530770%2FS1053077011X00071%2Fcov150h.gif |